We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes (NIR)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01707979
First Posted: October 16, 2012
Last Update Posted: October 16, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Lise Tarnow, Steno Diabetes Center
September 25, 2012
October 16, 2012
October 16, 2012
September 2012
October 2012   (Final data collection date for primary outcome measure)
near infrared spectroscopy [ Time Frame: one time ]
Near infrared (NIR) is measured by spectroscopy on the skin using the DDD probe
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes
NIR (Near Infrared)- Spectroscopy and Multifrequent Impedance Spectroscopy on the Skin to Detection of Sensory and Autonomic Neuropathy Among Patients With Type 1 Diabetes
The aim of the study is to examine the suitability to detect diabetic neuropathy using NIR and impedance.

The aim of the study is to examine how suitable a hand-held measuring probe (DDD-probe) using NIR (near infrared light) as well as impedance (conductivity), is to detect early signs of diabetic neuropathy.

The DDD-probe is put directly on the skin and is measuring by the use of light and impedance.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
Control group men without diabetes Type1 diabetic men without neuropathy complications Type 1 diabetic men with neuropathy complications
Diabetic Neuropathy
Not Provided
  • Diabetic neuropathy
    Male participants, type1 diabetic with diabetic neuropathy
  • Diabetes without neuropathy
    Male participants, type1 diabetic without diabetic neuropathy
  • Non diabetic control
    Male participants, control group non diabetic
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
October 2012
October 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • men with type 1 diabetes (WHO criteria)
  • age 35-50 years
  • duration of diabetes > 10 years

Exclusion Criteria:

  • P-creatinine> 120 micromol/l
  • other acute or chronic disease, or type of treatment that makes the patient unsuitable to participate, valuated by the investigator
  • non intact skin on the measuring spots
  • the patient is unable to understand the informed consent
Sexes Eligible for Study: Male
35 Years to 50 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT01707979
NIR
Yes
Not Provided
Not Provided
Lise Tarnow, Steno Diabetes Center
Lise Tarnow
Not Provided
Principal Investigator: Lise Tarnow, Professor Steno Diabetes Center
Steno Diabetes Center
October 2012